Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update
Cannabis Law Report
NOVEMBER 12, 2021
AUSTIN, Texas–(BUSINESS WIRE)– Anebulo Pharmaceuticals, Inc. Completed manufacturing of ANEB-001 capsules for upcoming Phase 2 clinical trial. On track to commence Phase 2 proof-of-concept clinical trial with ANEB-001 for the treatment of acute cannabinoid intoxication by year-end.
Let's personalize your content